There are multiple Immune therapies against cancer including the use of therapeutic molecules, such as immune checkpoint inhibitors, antibodies against tumor-specific antigens, and vaccines, and cellular therapies, as well as those utilizing genetically modified immune cells. Despite the above therapies gaining tremendous successes, there is still a need for a novel type of immune therapy approach against cancer. At present, most immune therapies focus on modifying the function of T-lymphocyte. In contrast, a new modality called immune system engagers (ISErs) follows a different mode of action, in which they primarily target innate immune cells, especially myeloid cells. With the experience research team and advanced instrument, Creative Biolabs offers the NewFlexi™ ISErs technology platform to achieve the activation of the first line of immune defense to fight cancer cells.
Creative Biolabs' novel and innovative concept reprogramming the patient's immune system to fight specifically against cancer by small, completely chemically derived molecules called ISErs. ISErs contain two or more tumor-targeting peptides and an immune-stimulating effector peptide connected by inert polymer linkers (as shown as Fig.1). All of them are produced by solid-phase peptide synthesis and share the specific targeting activities of antibodies (IgGs) but are much smaller in size and exploit a different immune-stimulating mechanism.
Fig.1 ISErs concept. (Pötgens, 2019)
As a novel class of synthetic peptide-based compounds that bind specifically to cancer cells and stimulate the immune system, ISErs have the following properties:
ISErs combine highly selective binders to recognize cancer cells and immune activators in one small molecule of 5 to 10 kD. The molecules of ISErs are simple in chemical production and extremely flexible in design, which can be designed to the needs to fight against specific cancer. Except for the immune activator, an ISEr haves up to four different binder arms targeting multiple cancer cell-specific markers. Moreover, ISErs can be produced chemically within only a few days with low costs due to such flexible molecules.
Many in vitro and in vivo studies have shown that ISErs are strong agents to fight against tumors and metastases. Brehs. et al. have demonstrated that the anti-tumor activity and synthetic accessibility of Y9 illustrate that ISErs could be applied to a wide variety of diseases. In addition, metastasis is seen as one important factor for a bad prognosis in the development of cancer. The pipeline of ISEr targets many hard-to-treat cancers in different development stages. Creative Biolabs is working consequently to extend this promising pipeline.
For more details about our NewFlexi™ ISErs technology platform, please do not hesitate to contact us.
References
For Research Use Only | Not For Clinical Use
Download our brochure